IBS-C薬の世界市場2020-2061

◆英語タイトル:GLOBAL IBS-C DRUG MARKET FORECAST 2020-2028
◆商品コード:INK20MY050
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2020年2月
◆ページ数:211
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥262,500見積依頼/購入/質問フォーム
Multi LicenseUSD3,000 ⇒換算¥315,000見積依頼/購入/質問フォーム
Enterprisewide PriceUSD4,500 ⇒換算¥472,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートではIBS-C薬の世界市場について調査・分析し、調査範囲・手法、エグゼクティブサマリー、市場動向、主要分析、処方別(処方薬、商標、ジェネリック、市販薬)分析、医薬品別(ルビプロストン、リナクロチド、刺激性下剤、ビサコジル、その他)分析、地域別分析、企業情報などの情報をお届けいたします。
・調査範囲・手法
・エグゼクティブサマリー
・市場動向
・主要分析
・IBS-C薬世界市場:処方別(処方薬、商標、ジェネリック、市販薬)
・IBS-C薬世界市場:医薬品別(ルビプロストン、リナクロチド、刺激性下剤、ビサコジル、その他)
・地域別分析
・企業情報
【レポートの概要】

KEY FINDINGS
The global IBS-C drug market is estimated to grow and record a CAGR of 9.21% during the forecast period, 2020-2028. The factors augmenting the global market growth are growing lifestyle-oriented diseases, an increase in healthcare expenditure, severe gastrointestinal infection, an increasing number of patients suffering from depression, and medical advancements.

MARKET INSIGHTS
Irritable bowel syndrome (IBS) is prevalent in the general population and has affected adversely in terms of substantial and socio-economic impact. There are about 10-20% of the population experiencing symptoms of IBS, but 15% of affected individuals seek medical treatment. Due to highly prevailing modern dietary habits, such as intake of fried foods, insoluble fiber, and excessive consumption of alcohol and caffeine, there is a rise in the number of people suffering from IBS. The factors acting as market constraints are strict FDA regulations and ignorance among people. There are some serious after-effects of the drugs used to treat IBS. Thus, the industry suffers from strict regulations from the FDA and other regulatory authorities, leading to many drugs being called off from the market and or not approved by the FDA. Competition is high among the existing players in the market due to the presence of a few approved therapies. Companies are competing with each other by providing the products with similar features at similar or lower prices, and also by acquiring major companies.

REGIONAL INSIGHTS
The global IBS-C drug market is analyzed geographically on the basis of markets situated across the region of North America, Europe, Asia Pacific, and the Rest of the World. As of 2019, the region of North America holds the largest market share in terms of revenue, and continues the trend by the end of the forecast period. This is attributed to the government initiative to improve the healthcare sector by providing the latest technological medication and advanced treatment support.

COMPETITIVE INSIGHTS
Novartis, Teva Pharmaceutical Industries, Catalent Pharma Solutions, Actavis Nordic, Yuhan Corp., etc. are some of the prominent players registering their presence in the global market.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. MARKET DEFINITION
3.2. KEY DRIVERS
3.2.1. MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
3.2.2. IBS CAN BE A HERITABILITY ISSUE
3.2.3. AVAILABILITY OF EFFECTIVE DRUGS IN THE MARKET
3.3. KEY RESTRAINTS
3.3.1. STRICT FDA REGULATIONS
3.3.2. UNAWARENESS AND IGNORANCE AMONG PEOPLE
4. KEY ANALYTICS
4.1. KEY INVESTMENT INSIGHTS
4.2. PORTER’S FIVE FORCE ANALYSIS
4.2.1. BUYER POWER
4.2.2. SUPPLIER POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. OPPORTUNITY MATRIX
4.4. VENDOR LANDSCAPE
4.5. REGULATORY FRAMEWORK
5. MARKET BY PRESCRIPTION TYPE
5.1. PRESCRIBED
5.1.1. BRANDED
5.1.2. GENERIC
5.2. OVER THE COUNTER
6. MARKET BY DRUG TYPE
6.1. LUBIPROSTONE
6.2. LINACLOTIDE
6.3. STIMULANT LAXATIVES
6.3.1. BISACODYL
6.3.2. SENNA
6.4. OSMOTIC LAXATIVES
6.4.1. LACTULOSE
6.4.2. POLYETHYLENE GLYCOL
6.5. OTHER DRUG TYPES
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. UNITED STATES
7.1.2. CANADA
7.2. EUROPE
7.2.1. UNITED KINGDOM
7.2.2. GERMANY
7.2.3. FRANCE
7.2.4. ITALY
7.2.5. RUSSIA
7.2.6. BELGIUM
7.2.7. POLAND
7.2.8. REST OF EUROPE
7.3. ASIA PACIFIC
7.3.1. CHINA
7.3.2. JAPAN
7.3.3. INDIA
7.3.4. SOUTH KOREA
7.3.5. INDONESIA
7.3.6. THAILAND
7.3.7. VIETNAM
7.3.8. AUSTRALIA & NEW ZEALAND
7.3.9. REST OF ASIA PACIFIC
7.4. REST OF WORLD
7.4.1. LATIN AMERICA
7.4.2. MIDDLE EAST & AFRICA
8. COMPANY PROFILES
8.1. CATALENT PHARMACEUTICALS SOLUTIONS
8.2. ABBOTT LABORATORIES
8.3. NOVARTIS PHARMA AG
8.4. ASTELLAS PHARMACEUTICALS
8.5. ARDELYX, INC.
8.6. SYNTHETIC BIOLOGICS, INC.
8.7. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
8.8. BAMA-GEVE, SLU
8.9. FERRING BV
8.10. IRONWOOD PHARMACEUTICALS, INC.
8.11. SALIX PHARMACEUTICALS LTD.
8.12. NORGINE B.V.
8.13. PROMETHEUS LABORATORIES, INC.
8.14. ALBIREO PHARMA, INC.
8.15. YUHAN CORP.
8.16. ASTRAZENECA PLC
8.17. THE MENARINI GROUP
8.18. ONO PHARMACEUTICAL CO. LTD.
8.19. ACTAVIS NORDIC A/S

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – IBS-C DRUG
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: GLOBAL IBS-C DRUG MARKET, BY PRESCRIPTION TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 4: GLOBAL IBS-C DRUG MARKET, BY PRESCRIPTION TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 5: GLOBAL PRESCRIBED MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 6: GLOBAL PRESCRIBED MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 7: GLOBAL IBS-C DRUG MARKET, BY PRESCRIBED, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 8: GLOBAL IBS-C DRUG MARKET, BY PRESCRIBED, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 9: PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
TABLE 10: GLOBAL BRANDED MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 11: GLOBAL BRANDED MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 12: GLOBAL GENERIC MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 13: GLOBAL GENERIC MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 14: GLOBAL OVER THE COUNTER MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 15: GLOBAL OVER THE COUNTER MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 16: GLOBAL IBS-C DRUG MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 17: GLOBAL IBS-C DRUG MARKET, BY DRUG TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 18: PRODUCT PROFILE (LUBIPROSTONE)
TABLE 19: GLOBAL LUBIPROSTONE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 20: GLOBAL LUBIPROSTONE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 21: PRODUCT PROFILE (LINACLOTIDE)
TABLE 22: GLOBAL LINACLOTIDE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 23: GLOBAL LINACLOTIDE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 24: GLOBAL STIMULANT LAXATIVES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 25: GLOBAL STIMULANT LAXATIVES MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 26: GLOBAL IBS-C DRUG MARKET, BY STIMULANT LAXATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 27: GLOBAL IBS-C DRUG MARKET, BY STIMULANT LAXATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 28: PRODUCT PROFILE (BISACODYL)
TABLE 29: GLOBAL BISACODYLMARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 30: GLOBAL BISACODYLMARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 31: PRODUCT PROFILE (SENNA)
TABLE 32: GLOBAL SENNA MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 33: GLOBAL SENNA MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 34: GLOBAL OSMOTIC LAXATIVES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 35: GLOBAL OSMOTIC LAXATIVES MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 36: GLOBAL IBS-C DRUG MARKET, BY OSMOTIC LAXATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 37: GLOBAL IBS-C DRUG MARKET, BY OSMOTIC LAXATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 38: PRODUCT PROFILE (LACTULOSE)
TABLE 39: GLOBAL LACTULOSE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 40: GLOBAL LACTULOSE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 41: PRODUCT PROFILE (POLYETHYLENE GLYCOL)
TABLE 42: GLOBAL POLYETHYLENE GLYCOL MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 43: GLOBAL POLYETHYLENE GLYCOL MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 44: PRODUCT PROFILE (PSYLLIUM)
TABLE 45: GLOBAL OTHER DRUG TYPES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 46: GLOBAL OTHER DRUG TYPES MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 47: GLOBAL IBS-C DRUG MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 48: GLOBAL IBS-C DRUG MARKET, BY GEOGRAPHY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 49: NORTH AMERICA IBS-C DRUG MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 50: NORTH AMERICA IBS-C DRUG MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 51: EUROPE IBS-C DRUG MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 52: EUROPE IBS-C DRUG MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 53: ASIA PACIFIC IBS-C DRUG MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 54: ASIA PACIFIC IBS-C DRUG MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 55: REST OF WORLD IBS-C DRUG MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 56: REST OF WORLD IBS-C DRUG MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
LIST OF FIGURES
FIGURE 1: DRUGS PULLED OFF FROM THE MARKET
FIGURE 2: KEY INVESTMENT INSIGHTS
FIGURE 3: PORTER’S FIVE FORCE ANALYSIS
FIGURE 4: OPPORTUNITY MATRIX
FIGURE 5: VENDOR LANDSCAPE
FIGURE 6: GLOBAL IBS-C DRUG MARKET, GROWTH POTENTIAL, BY PRESCRIPTION TYPE, IN 2019
FIGURE 7: GLOBAL IBS-C DRUG MARKET, PRESCRIBED, 2020-2028 (IN $ MILLION)
FIGURE 8: GLOBAL IBS-C DRUG MARKET, BRANDED, 2020-2028 (IN $ MILLION)
FIGURE 9: GLOBAL IBS-C DRUG MARKET, GENERIC, 2020-2028 (IN $ MILLION)
FIGURE 10: GLOBAL IBS-C DRUG MARKET, OVER THE COUNTER, 2020-2028 (IN $ MILLION)
FIGURE 11: GLOBAL IBS-C DRUG MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2019
FIGURE 12: GLOBAL IBS-C DRUG MARKET, LUBIPROSTONE, 2020-2028 (IN $ MILLION)
FIGURE 13: GLOBAL IBS-C DRUG MARKET, LINACLOTIDE, 2020-2028 (IN $ MILLION)
FIGURE 14: GLOBAL IBS-C DRUG MARKET, STIMULANT LAXATIVES, 2020 -2028 (IN $ MILLION)
FIGURE 15: GLOBAL IBS-C DRUG MARKET, BISACODYL, 2020-2028 (IN $ MILLION)
FIGURE 16: GLOBAL IBS-C DRUG MARKET, SENNA, 2020-2028 (IN $ MILLION)
FIGURE 17: GLOBAL IBS-C DRUG MARKET, OSMOTIC LAXATIVES, 2020 -2028 (IN $ MILLION)
FIGURE 18: GLOBAL IBS-C DRUG MARKET, BISACODYL, 2020-2028 (IN $ MILLION)
FIGURE 19: GLOBAL IBS-C DRUG MARKET, POLYETHYLENE GLYCOL, 2020-2028 (IN $ MILLION)
FIGURE 20: GLOBAL IBS-C DRUG MARKET, OTHER DRUG TYPES, 2020 -2028 (IN $ MILLION)
FIGURE 21: NORTH AMERICA IBS-C DRUG MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
FIGURE 22: UNITED STATES IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 23: CANADA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 24: EUROPE IBS-C DRUG MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
FIGURE 25: UNITED KINGDOM IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 26: GERMANY IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 27: FRANCE IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 28: ITALY IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 29: RUSSIA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 30: BELGIUM IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 31: POLAND IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 32: REST OF EUROPE IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 33: ASIA PACIFIC IBS-C DRUG MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
FIGURE 34: CHINA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 35: CHINESE MEDICINE TCM TREATMENT FOR IBS
FIGURE 36: JAPAN IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 37: INDIA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 38: SOUTH KOREA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 39: INDONESIA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 40: THAILAND IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 41: VIETNAM IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 42: AUSTRALIA & NEW ZEALAND IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 43: REST OF ASIA PACIFIC IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 44: REST OF WORLD IBS-C DRUG MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
FIGURE 45: LATIN AMERICA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 46: MIDDLE EAST & AFRICA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[IBS-C薬の世界市場2020-2061]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆